Adenosine A2A receptor antagonists in Parkinson's disease: Still in the running

The Lancet Neurology

Volumn 13, Issue 8, 2014, Pages 748-749

  Antonini, Angelo ^a   Poewe, Werner ^b  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PRELADENANT; RASAGILINE; TOZADENANT; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT;

DEATH; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG SAFETY; DYSKINESIA; FOOD AND DRUG ADMINISTRATION; HUMAN; JAPAN; MOTOR CONTROL; NAUSEA; NONHUMAN; NOTE; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); UNITED STATES; FEMALE; MALE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE;

EID: 84907022085     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70153-X     Document Type: Note

References (10)

1. Poewe WH, Lees AJ, Stern GM Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986, 36:1528-1530.
2. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011, 258:579-585.
3. Kalia LV, Brotchie JM, Fox SH Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord 2013, 28:131-144.
4. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003, 184:285-294.
5. 2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013, 28:1138-1141. Japanese Istradefylline Study Group.
6. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012, 18:178-184.
7. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011, 10:221-229.
8. Merck provides update on phase III clinical program for preladenant, the company's investigational Parkinson's disease medicine Merck, (accessed June 20, 2014). http://www.businesswire.com/news/home/20130523006358/en/Merck-Update-Phase-III-Clinical-Program-Preladenant.
9. Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014, published online July 7. http://dx.doi.org/10.1016/S1474-4422(14)70148-6.
10. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954. for the LARGO study group.